Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SLV308 in Advanced Parkinson's Disease
NCT00134251Phase 3Completed
- Sponsor
- Solvay
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of pardoprunox in Parkinson's disease (PD), sponsored by Solvay. Started Oct 2005; status: completed.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00134251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134251.